{"database":"biostudies-literature","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":49,"searchCount":0},"additional":{"submitter":["Ding X"],"funding":["National Natural Science Foundation of China"],"pagination":["547-554"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7214645"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(3)"],"pubmed_abstract":["This study aimed at exploring the concentration-effect relationship of adalimumab and early adalimumab and anti-adalimumab antibody (AAA) levels in predicting primary nonresponse in a real-world pilot cohort of patients with ankylosing spondylitis. Thirty-one patients were included. The Ankylosing Spondylitis Disease Activity Score improved with increasing adalimumab trough level at week 12 and reached a major improvement with levels between 8 and 12 μg/mL. Moreover, weeks 4 and 2 adalimumab levels below 4.28 and 3.37 μg/mL were predictive of primary nonresponse (area under the curve (AUC) = 0.89, 0.88; P = 0.0003, P = 0.034, respectively). Week 4 AAA signal-to-noise levels were significantly higher among primary nonresponders, and the cutoff for primary nonresponse prediction was above 5.31 (AUC = 0.81; P = 0.004). Adalimumab trough levels in a range of 8-12 μg/mL are optimum to reach major improvement, and lower adalimumab with higher AAA levels at the early stage (week 4) predict primary nonresponse by supporting proactive monitoring to optimize adalimumab therapy."],"journal":["Clinical and translational science"],"pubmed_title":["Early Adalimumab and Anti-Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients."],"pmcid":["PMC7214645"],"funding_grant_id":["81773820"],"pubmed_authors":["Wu J","Ding X","Gu M","Xue L","Zhu R","Miao L"],"view_count":["49"],"additional_accession":[]},"is_claimable":false,"name":"Early Adalimumab and Anti-Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients.","description":"This study aimed at exploring the concentration-effect relationship of adalimumab and early adalimumab and anti-adalimumab antibody (AAA) levels in predicting primary nonresponse in a real-world pilot cohort of patients with ankylosing spondylitis. Thirty-one patients were included. The Ankylosing Spondylitis Disease Activity Score improved with increasing adalimumab trough level at week 12 and reached a major improvement with levels between 8 and 12 μg/mL. Moreover, weeks 4 and 2 adalimumab levels below 4.28 and 3.37 μg/mL were predictive of primary nonresponse (area under the curve (AUC) = 0.89, 0.88; P = 0.0003, P = 0.034, respectively). Week 4 AAA signal-to-noise levels were significantly higher among primary nonresponders, and the cutoff for primary nonresponse prediction was above 5.31 (AUC = 0.81; P = 0.004). Adalimumab trough levels in a range of 8-12 μg/mL are optimum to reach major improvement, and lower adalimumab with higher AAA levels at the early stage (week 4) predict primary nonresponse by supporting proactive monitoring to optimize adalimumab therapy.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 May","modification":"2024-11-20T11:00:16.124Z","creation":"2020-05-22T20:00:32Z"},"accession":"S-EPMC7214645","cross_references":{"pubmed":["31961477"],"doi":["10.1111/cts.12738"]}}